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Background: Syndromic forms of osteosarcoma (OS) account for less than 10% of all recorded cases of this malignancy.
An individual OS predisposition is also possible by the inheritance of low penetrance alleles of tumor susceptibility genes,
usually without evidence of a syndromic condition. Genetic variants involved in such a non-syndromic form of tumor
predisposition are difficult to identify, given the low incidence of osteosarcoma cases and the genetic heterogeneity of
patients. We recently mapped a major OS susceptibility QTL to mouse chromosome 14 by comparing alpha-radiation
induced osteosarcoma in mouse strains which differ in their tumor susceptibility.
Methods: Tumor-specific allelic losses in murine osteosacoma were mapped along chromosome 14 using microsatellite
markers and SNP allelotyping. Candidate gene search in the mapped interval was refined using PosMed data mining and
mRNA expression analysis in normal osteoblasts. A strain-specific promoter variant in Rb1 was tested for its influence on
mRNA expression using reporter assay.
Results: A common Rb1 allele derived from the BALB/cHeNhg strain was identified as the major determinant of
radiation-induced OS risk at this locus. Increased OS-risk is linked with a hexanucleotide deletion in the promoter region
which is predicted to change WT1 and SP1 transcription factor-binding sites. Both in-vitro reporter and in-vivo expression
assays confirmed an approx. 1.5 fold reduced gene expression by this promoter variant. Concordantly, the 50% reduction
in Rb1 expression in mice bearing a conditional hemizygous Rb1 deletion causes a significant rise of OS incidence
following alpha-irradiation.
Conclusion: This is the first experimental demonstration of a functional and genetic link between reduced Rb1
expression from a common promoter variant and increased tumor risk after radiation exposure. We propose that a
reduced Rb1 expression by common variants in regulatory regions can modify the risk for a malignant transformation of
bone cells after radiation exposure.
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The relatively low incidence of osteosarcoma (OS) in the
general population increases dramatically in cases of high–
penetrance cancer syndromes such as Li-Fraumeni, familial
retinoblastoma or Werner- and Rothmund-Thompson syn-
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article, unless otherwise stated.evidence of an underlying tumor syndrome is rare, and it is
possible that this is due to a chance observation or shared
environmental risk factor [2-4]. Nevertheless, association
between osteosarcoma and other tumor types in relatives
does occur [5,6], suggesting that undiscovered germline fac-
tors may contribute to osteosarcoma risk. The existence of
congenital, low-penetrance tumor predisposition associated
with OS in non-syndromic patients was also concluded in a
study of 938 Dutch osteosarcoma patients, in which a 2.4
fold increased risk of developing an additional tumor in
another organ was found [7]. In the case of Li-Fraumenitral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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penetrance cancer-prone conditions with a predispos-
ition for OS, a subset of the affected patients had not
been found to carry germline mutations in the prototyp-
ical TP53 gene [8] or in the RB1 coding sequence [9]. It
is therefore likely that phenocopies of these OS linked
syndromes are caused by mutations in other genes af-
fecting the same pathways, or that yet undiscovered
hypomorphic allelic variants of established susceptibility
genes modify tumor risk [9,10]. The presence of such
low-penetrance gene variants would imply that a much
larger than previously estimated fraction of tumors may
be due to a congenital predisposition [11,12]. Since fa-
milial clustering would be very unlikely to occur in such
conditions [13], population-based genome-wide associ-
ation studies (GWAS) or whole-genome sequence ana-
lysis in patients might help to map the underlying gene
variants, but might be hampered by low statistical
power. A recent multi-center GWAS study on osteosa-
coma identified 2 novel candidate loci for OS suscepti-
bility with odds-ratios of 1.57 and 1.39, respectively
[14]. The missing association with established OS risk
genes such as TP53, RB1, WRN or RECQL4 in this
study, however points to the problem of small patient
number and genetic and phenotypic heterogeneity for
this tumor type.
Strain differences between genetically defined mouse
inbred strains have been used successfully to identify
genes and allelic variants which influence predisposition
for spontaneous or carcinogen-induced malignancies
[15-18]. For osteosarcoma, the only established exogen-
ous carcinogen is ionizing radiation, in particular by in-
corporation of bone-seeking radio-isotopes in the event
of medical or occupational exposure. This observation was
confirmed in animal models such as dogs and rodents,
and variations in the OS susceptibility between different
mouse inbred strains were reported [19]. We recently used
a mouse model to map several osteosarcoma susceptibility
loci in the murine genome using QTL analysis [20,21].
These studies established that the principal susceptibility
locus spans an approximately 46 Mbp interval on the dis-
tal part of mouse chromosome 14.
The large number of mapped genes and non-coding
transcripts in the D14Mit90 to D14Mit225 interval, to-
gether with the general problem of deducing a causal
relationship from forward genetics, precluded any infer-
ence to a single susceptibility gene at this locus. For this
purpose, more precise and complementary mapping
strategies are necessary to reduce the number of candi-
date susceptibility genes such that functional studies are
feasible. In the present study we combined mapping of
tumor-specific allele-losses across the susceptibility
locus with positional-candidate mapping and identified
a functional gene polymorphism in Rb1.Results and discussion
Identification of candidate genes
We have previously shown that an interval on murine
chromosome Mmu 14 (72.3 – 118 Mbp) contains the prin-
cipal locus conferring susceptibility to alpha-radiation in-
duced osteosarcoma in four different mouse strains [20,21].
(compound LOD score 4.4). Due to incomplete penetrance
of such a susceptibility gene, confounding causes of death
after irradiation, and the inherent stochastic nature of radi-
ation tumorigenesis a more precise mapping of this QTL
using linkage-analysis was not feasible. We have therefore
applied a complementary method to better define the pos-
ition of the susceptibility gene, using somatic allelic imbal-
ances mapping across this locus in osteosarcoma of (BALB/
cHeNhg × CBA/Ca)F1 mice. After 227Thorium incorpor-
ation at the age of 100 days, 17 out of 80 female F1 mice
developed osteosarcoma that were suitable for molecular
analysis (median latency time = 553 days, range from 290 to
766 days). In 13 out of 17 of these tumors we observed al-
lelic loss or imbalance for at least one marker between
D14Mit234 and D14Mit97, i.e. within the principle OS sus-
ceptibility locus on chromosome 14 [21] (Figure 1). In 10/
13 cases the maternal (BALB/c) allele was affected, whereas
the paternal CBA allele was lost in the remaining 3 cases.
This preferential loss of 10 BALB/c versus 3 CBA alleles
(p = 0.014, relative to a total of 34 parental chromosomes)
is consistent with the assumption that tumors in heterozy-
gous F1 gain a growth advantage when they somatically
lose an allele that confers relative resistance. We observed
before that in the progeny of (BALB/cHeNhg × CBA/Ca)
F1 mice backcrossed to female BALB/cHeNhg (further re-
ferred to as BBC) the BALB/c allele at this locus is associ-
ated with relative OS resistance [21]. The smallest common
interval of overlapping allelic imbalances spans 2.654 Mbp
(between D14Mit90 and D14Mit 225, Figure 1) and en-
compasses 12 known genes, 1 protein-coding gene with
unknown function, 2 non-coding RNA genes and 1
pseudogene (Additional file 1). To nominate candidate
genes from this genomic interval, we used PosMed, a
search engine based on the entire biomedical literature
to find links between a set of genes and a given pheno-
type [22]. Here we identified 7 genes in the D14Mit90/
D14Mit225 interval (Rb1, Esd, Cysltr2, Htr2a, Fndc3a,
Ltm2b, Lpar6) with a potential function in osteosar-
coma susceptibility (Additional file 2). Of these 7 genes,
only Rb1 is directly associated with osteosarcoma as sug-
gested by 12 studies (p = 5 × 10−53) whereas the other 6
candidates are linked to osteosarcoma indirectly, either via
additional genes acting in-trans or through comorbidity
(next best p-value 1.1 × 10−20 for Esd). It is also worth
mentioning that according to the Mouse Genome Inform-
atics database, some modifier loci for other traits have
been mapped to this interval (such as Modor3 for ocular













Figure 1 Analysis of allelic imbalance in 17 osteosarcomas induced in (BALB/cHeNhg x CBA/Ca)F1 hybrid mice. Pattern of allelic
imbalances at the Rb1 locus and at flanking microsatellite markers are shown as grey bars (retention of heterozygosity), pink bars (reduction or
loss of the BALB allele) or white bars (reduction or loss of the CBA allele).
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quences, we limited our screen to genes and other tran-
scribed elements as validated in the current mouse genome
release (NCBI GRCm38).
The link between RB1 and osteosarcoma is mainly based
on missense and nonsense mutations in the germline
which predispose for retinoblastoma in children and OS
in adolescents [23]. Following high-dose radiotherapy for
primary retinoblastoma in these patients, the risk of a sec-
ondary OS is potentiated [24]. We therefore analysed the
pattern of allelic imbalances or loss-of-heterozygosity
(LOH) across this minimal deleted interval, using poly-
morphic microsatellite markers and an intragenic SNP at
the Rb1 3’UTR (Additional file 3). LOH breakpoints were
found between the distal (D14Mit225) markers and Rb1 in
three tumors, two of which also had breakpoints in the
proximal interval between D14Mit90 and Rb1 (Figure 1).
Expression of candidate genes
We further reasoned that any susceptibility gene for
osteosarcoma must be expressed in the relevant target
cells in order to influence the tumor risk. We therefore
measured the mRNA expression in murine osteoblasts
of all genes and none-coding elements as derived from
the current release of the mouse genome in this interval(Additional file 1). We found that except for three of them
with undetectable expression (Nudt15, Med4, miRNA687-
hom), the relative expression level in the MC3T3 preosteo-
blastic cell-line and in-vitro explanted osteoblasts varied
between 0.15 fold (Cysltr2) and 3.7 fold (Ltm2b) relative to
whole embryo mRNA (Additional file 4).
Rb1 promoter variations
The classical view of genetic predisposition by a germline
loss-of-function RB1 allele followed by somatic losses of the
wt allele during progression of retinoblastoma is that even-
tually the tumor expresses the inherited allele which confers
high susceptibility in the germline.
We therefore expected to find a gene variation in the
CBA allele of Rb1 which can explain the association with
the higher OS risk. Sequencing the coding region of Rb1
from the BALB/cHeNhg and CBA/Ca strain, we found only
nucleotide variations in the 3’ UTR, but as they did not
map to known mRNA stability motifs they were not con-
sidered of major functional relevance [25]. Missense and
non-sense RB1 mutations, which account for about 80% of
heritable retinoblastoma and osteosarcoma cases in patients
[26-28], can therefore be ruled out in our case. In addition
to coding sequence RB1 mutations associated with highly
penetrant phenotypes in humans, a small subset of cases
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penetrance, sometimes caused by mutations that affect RB1
promoter methylation sites [9,29-31]. An association of
these low-penetrance gene mutations with OS predispos-
ition, however, was never found, but might have been
missed due to the scarcity of such families and the general
low OS incidence.
In fact, we found a CBA/Ca specific TCGCCC hexanu-
cleotide deletion in the Rb1 promoter, located 271 nt up-
stream of the ATG start and 78 nt upstream of the binding
sites for Sp1, ATF and E2F in the promoter core (Figure 2a,
b) [32]. In-silico analysis using the tool MathInspector
[33,34] to analyze changes in TF binding sites predicted
that this hexanucleotide InDel could delete a WT1 TF
binding site and disrupt a SP1-SP1 module (Additional
file 5) [35].
Impact on Rb1 promoter activity and gene expression
To test the impact of these predicted TF binding site alter-
ations on gene expression, we applied both an in-vitro
promoter reporter assay as well as direct quantification of
Rb1 transcripts in whole embryos of BALB/cHeNhg and
CBA/Ca mouse strains. Rb1 promoter fragments encom-
passing the ubiquitous SP1, ATF and E2F binding sites to-
gether with the site of the Δ(TCGCCC) variation from
both mouse strains (Additional file 6) were able to activate
a CAT reporter gene in an orientation-dependent and re-
producible manner (Figure 3a) after transient transfection
of ROS17/2.8 rat osteoblasts. Quantification of the re-
porter activity from the two promoter variants confirmed
that the CBA–specific Δ(TCGCCC) deletion produced
less CAT-activity (2.42 AU, CI 2.19 – 2.65) when com-
pared to the BALB/c allele (4.38 AU, CI 4.19 – 4.57,
Figure 3b). This 1.8 fold difference is highly significant
(p = 0.0003, t-test). An inverse orientation of the Rb1 pro-
moter fragment shows only 21% activity and extracts from
mock-transfected cells have less than 8.3% basal activity
relative to the BALB/c construct. A difference was also
found in the average Rb1 gene expression of day 16
whole embryo extracts, being lower in CBA/Ca (183
AU, CI 138 – 228) than in the BALB/cHeNhg strain
(232 AU, CI 165 – 299, p = 0.038, t-test, Additional file 7).
Whereas the 1.28 fold reduced mRNA expression in
whole-embryo might be a more realistic value in view of
the natural genomic context of the Rb1-gene, the 1.8 fold
lower promoter activity in transfected osteoblasts could
reflect some bone-specific regulation of the Rb1 promoter.
It is interesting to note that although the essential TF-
binding sites in the core promoter of the Rb1 gene are
not affected by this alteration, suggesting that transcrip-
tion is still possible, two Rb1 control elements map
within a 20 bp interval around this hexanucleotide indel
[36]. Recently it was shown that these RCEs and other
undiscovered sequence elements in-cis of the RB1 corepromoter site are crucial for transcriptional fine-tuning
in a tissue-specific manner. They are also involved in
regulating the RB1 protein homeostasis through feed-
back loops involving all 3 Rb family proteins members,
including a RB1 autosuppression [37].
If for practical purposes we consider a 1.5 fold lower
Rb1 expression in homozygous CBA/Ca osteoblasts (i.e.
the average between the reporter assay and the in-vivo
embryo mRNA level), then the overall Rb1-expression
from both alleles in heterozygous BALB/CBA osteoblasts
would be reduced to about 83% as compared to 100% in
homozygous BALB/BALB osteoblasts (after loss of the
BALB/c allele in OS, expression in malignant osteoblasts
could further drop to approximately 67%).
Δ(TCGCCC) Rb1 promoter variant and the risk for Th227
induced OS
The impact of this reduced Rb1 expression in normal
osteoblast cells for the risk to develop osteosarcoma after
Th227-incorporation can be inferred from re-genotyping
the BALB/cHeNhg × (BALB/cHeNhg × CBA/Ca) back-
cross [21] for the Rb1 promoter variant (Figure 2c). Out of
169 backcrossed mice, 93 inherited the BALB/CBA geno-
type at the Rb1 promoter, of which 23 (or 24.7%) devel-
oped an OS. Of the 76 mice inheriting the BALB/BALB
genotype, only 10 were diagnosed with a tumor (13.2%,
p = 0.016, Fisher’s exact test). In addition to increased
tumor incidence, the Δ(TCGCCC) promoter variant in the
CBA-allele is also linked to a shorter tumor latency (p =
0.0007, Log-Rank test) (Figure 2c).
The potential impact of reduced RB1 expression for the
carcinogenic process
The canonical function of RB1 as a prototype tumor-
suppressor gene is based on its ability to regulate the G1/S
cell-cycle transition by sequestration of E2F-transcription
factors. In bilateral retinoblastoma, this gatekeeper func-
tion is completely abolished after loss-of-heterozygosity in
carriers of a RB1 germline mutation. In osteosarcoma, al-
though frequently affected by RB1 allelic losses [38],
complete absence of gene expression is rarely seen, indi-
cating that a residual function of the wt RB1 protein is
compatible with or maybe even accelerates OS growth
(Additional file 8). A residual expression was also shown
in the majority of other cancer cell lines and tumors ex-
cept retinoblastoma [26,39], suggesting that reduced ex-
pression, but not complete absence of RB1 promotes
tumorigenesis
Apart from the canonical RB1 function as a key cell
cycle regulator, recent studies also point to its involvement
in non-canonical pathways such as regulation of pancen-
tromeric heterochromatin [40], mitotic checkpoint control
[41] and telomere maintenance [42,43]. We have recently
shown that Rb1 haplo-insufficiency results in a more rapid
CBA
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Ex1   
ATG
SP2 ATF  E2F
TCGCCC
InDel








































Figure 2 Rb1 Promoter polymorphism between BALB/cHeNhg and CBA/Ca mice. a: Sequence of the Rb1 promoter region between - 267
nt and – 288 nt determined for strains BALB/cHeNhg and CBA/Ca , showing structure of the BALB specific TCGCCC insertion. Base numbering
relative to ATG in exon 1. b: Position of the BALB specific hexanucleotide insertion relative to the SP1, ATF and E2F core binding sites according
to [32]. c: Association of the Rb1 promoter genotype in BALB/cHeNhg x (BALB/cHeNhg x CBA/Ca) backcrossed mice with osteosarcoma induction.
Kaplan-Meier plot of osteosarcoma appearance in 169 BALB/cHeNhg x (BALB/cHeNhg x CBA/Ca) backcrossed mice grouped according to their
genotypes at the Rb1 promoter. Mice inheriting the B/C genotype have a significantly shorter latency time and higher overall osteosarcoma
incidence than mice with the B/B genotype (p = 0.0007, Log-Rank Test). Of 79 mice inheriting the B/B genotype 14 developed an osteosarcoma,
whereas out of 90 mice with the B/C genotype 30 developed an osteosarcoma. Insert: PCR products following amplification of a 122/128 bp
fragment (primer 1005f and 1128r) encompassing the site of the BALB/c specific insertion. The insertion specific fragment was used for genotyping all mice
of the backcrossed cohort
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Figure 3 Analysis of transcriptional activity of the variant allele of the Rb1 promoter. a, CAT activity as measured by TLC chromatography
of ROS17/2.8 rat osteoblast protein extracts following transient transfection with the BALB/c and the CBA variants of Rb1 promoter fused to CAT
reporter constructs. b, Quantification of the CAT reporter signal driven by BALB/c (B) and CBA (C) promoter variants (positive orientation), CBA
promoter (inverse orientation) and mock-transfected cells (negC). Transfection efficiency was normalized by simultaneous measurement of
luciferase expression from co-transfected RFBpGL3 constructs
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bridges and micro-nuclei after gamma irradiation in mur-
ine osteoblasts [43].
One could make the point that these non-canonical
functions of RB1 are all involved in the maintenance of
genome integrity during cell division. An impaired func-
tion of either of these mechanisms could lead to the accu-
mulation of genetic or chromosomal defects, in particular
those which are transmitted from parental to daughter
cells. A defect in the canonical RB1 cell-cycle regulation,
on the other hand might disturb the growth rate of a cell
itself, but not necessarily increase genomic instability in
the progenitor cells. A transmission of chromosomal in-
stability from parent to daughter cells due to an impaired
RB1 function was also suggested by discovering its in-
volvement in the regulation of centromeric heterochroma-
tin, a key factor for a proper chromosome segregation
during mitosis [44]. In particular the genotoxic stress by
ionizing irradiation would require an efficient cellular sur-
veillance mechanism for genetic and chromosomal stabil-
ity to minimize the risk of malignant transformation [45].
Most epidemiological studies indicate that ionizing ir-
radiation can increase the number of solid tumors and leu-
kaemia, without changing the age distribution of their
diagnosis. This suggests that the rate of accumulating add-
itional genetic defects during tumor latency is a cell inher-
ent process and only marginally influenced by radiation.
The latency time, however shortens dramatically in the
event of a congenital tumor predisposition, therefore caus-
ing a rise in tumors in children or young adulthood. Re-
garding their pathobiology, radiation-induced OS with
latency times between 10 and 20 years therefore represent
tumors of the older patient group. But in combination with
an increased genetic susceptibility caused by an inheritedlow expressing RB1 allele, these tumors might shift to
younger age groups.
We hypothesize that a reduced RB1 expression ren-
ders normal cells more vulnerable to secondary genetic
changes, and that the resulting loss of genome stability
is a driving factor for tumorigenesis in itself. Rb1 hap-
loinsufficiency in murine ES cells was shown to increase
the rate of genetic instability [46], demonstrating that a
reduced gene expression can easily compromise genome
maintenance. Such a reduced capability of cells to ad-
equately respond to chromosomal defects could have
severe consequences after radiation exposure, consider-
ing that radiation-induced genotoxicity is mainly due to
the generation of DNA strand breaks.
Structural variants in the human RB1 promoter
The majority of RB1 germline mutations found in congeni-
tal retinoblastoma patients cause partial or complete loss of
the gene (41%) or frame shift and nonsense mutations
(42%) [26-28]. The remaining cases, some of which show
incomplete penetrance of the condition, are assumed to
carry germline mutations affecting regulatory elements of
the RB1 gene. It would therefore be worth systematically
testing non-syndromic OS patients for the presence of low-
penetrance RB1 promoter variants. Recent efforts to screen
the human genome for common variants have shown that
the RB1 promoter not only harbours several SNPs, but
at least two InDel variants. A hexanucleotide variation
(rs2092879) 1.5 kbp upstream of the human RB1 promoter
core was shown to alter TF binding and promoter activity
in vitro [47], whereas a 23bp InDel variant (rs36230211) is
located at a similar distance to the transcription start (221
bp proximal) as the murine InDel variation described here
(Figure 4). Considering that the human 23bp InDel
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Figure 4 Binding sites for transcription factors and regulatory proteins in the murine and the human Rb1 promoter (below the line)
and position of the reported indel polymorphisms (above line). TF binding sites in murine sequence as predicted by MatInspector software
[33,34] and as annotated by Zacksenhaus [32] (Genebank Acc.-No. M86180). TF binding sites in human sequence as predicted by [36]. Promoter
core consisting of steroid hormone response elements (HRE) and Sp1, ATF and E2F binding sites are highly conserved. Retinoblastoma control
elements (RCE) in the human promoter are according to [36] and predicted in the murine promoter using published RCE core sequences [48].
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that the structure of transcription factor binding sites in
this region is highly conserved from mouse to human
[32,36] one can assume that carriers of the human InDel
variant are also affected by a reduced RB1 expression. The
observations that a sufficient RB1 expression is instrumen-
tal for cells to prevent structural chromosomal defects
from being transmitted to the next cell generation sug-
gests, that a reduced RB1 level might result in a steady
accumulation of mutations and genomic instability in nor-
mal cells. This would cause a higher incidence of OS in
the group of older patients, but at the same time become
critical in the event of a genotoxic stress as caused by radi-
ation. It might therefore be interesting to search for the
presence of the above mentioned human RB1 promoter
variants in older OS patients and in those presenting with
a post-radiation, therapy associated tumor.
Conclusion
This is the first experimental demonstration of a functional
and genetic link between reduced Rb1 expression from a
common promoter variant and increased risk for osteosar-
coma after radiation exposure in mice. We propose that a
reduced Rb1 expression by common variants in regulatory
regions can modify the risk for a malignant transformation
of bone cells after radiation exposure.
The low phenotypic penetrance of such promoter or
regulatory variants spares them from significant selectionpressure, and hence increases their chance of becoming
fixed and more common in the population. We have
shown in this study that in combination with exogenous
genomic stress like ionizing radiation these low pene-
trance variations in RB1 can significantly alter the tumor
susceptibility of an organism.
Methods
Mouse breeding and tumor induction
All animal experiments were approved by the state govern-
ment (license no. RegOB 211-2531-49/00 and 211-2531-56/
06) and carried out in accordance with the federal animal
welfare guidelines. (BALB/cHeNhg × CBA/Ca)F1 and F1
mice backcrossed to female BALB/cHeNhg (further referred
to as BBC) mice were bred from HMGU Neuherberg
(formerly GSF) breeding stocks. For tumor induction, 80
(BALB/cHeNhg × CBA/Ca)F1 and 169 BBC mice (all fe-
male) were injected i.p. at the age of 100 days with a single
dose of 185Bq/g 227Th (as Thorium Citrate) [19]. Mice were
housed 5 to a cage and examined 5 days a week for the de-
velopment of tumors or other life-threatening conditions.
Bone tumors were diagnosed radiologically at necropsy
followed by histological examination after EDTA decalcifica-
tion. All malignant diseases were classified by trained clinical
and veterinary pathologists, using H&E and van-Gieson
staining. Typical histologies and X-ray images of tumors are
deposited in the PATHBASE database (http://eulep.pdn.
cam.ac.uk, Acc.No. 3410-3414, Acc.No. PB94713 ff).
Rosemann et al. Molecular Cancer 2014, 13:182 Page 8 of 11
http://www.molecular-cancer.com/content/13/1/182Statistical evaluation of osteosarcoma induction
Osteosarcoma-free survival curves, corrected for all com-
peting causes of death, were calculated using the Kaplan-
Mayer method. Significance of differences were tested with
the Statistika 6.0 software (StatSoft, Tulsa OK) using Cox’s
F- and LogRank-Test for tumor-free survival, two-tailed
Fisher’s exact test for fraction of tumor-bearing mice, one-
tailed Chi-square test of a four-field contingency table for
the allelic imbalances and t-test for the gene-expression
and reporter assays.
DNA extraction, microsatellite genotyping and
Rb1 sequencing
DNA for genotyping of mice was extracted from tail-tips
and from macro-dissected tumor-sections for measuring
allelic imbalances. Genomic PCR was done using primers
for polymorphic microsatellite markers and for the
Δ(TCGCCC) Rb1 promoter variant (Additional file 9). Reac-
tions were carried out in 96 well plates using a GeneAmp
9700 thermocycler (Applied Biosystems, Foster City, Ca,
USA) followed by 90min electrophoresis on 1.5% or 3%
agarose/TBE gels.
Analysis of allelic imbalance and LOH in osteosarcoma
Allelotyping of 17 osteosarcomas diagnosed in (BALB/
cHeNhg × CBA/Ca)F1 mice and of the paired normal
tissue was done for polymorphic microsatellite markers
on chromosome 14 (see above) by allel-specific PCR
and for a SNP in the Rb1 3’ UTR (3090nt) by genomic
sequencing. PCR-amplified microsatellite markers were
run for 90min electrophoresis in 3% agarose/TBE/EtBr
gels, the PCR products were visualized under UV illu-
mination, captured as 8 bit TIF-files on an electronic
DocuGel V system (Mitsubishi, Japan) and quantified
using the software package Intelligent Quantifier
(BioImage, Jackson MI). To validate linearity and sensitivity
of this assay, standard curves of the allelic ratios were
generated from BALB/CBA genomic DNA containing dif-
ferent percentages of pure BALB/c or pure CBA/Ca
DNA (Additional file 10).Candidate positional mapping using PosMed
The smallest common region affected by allelic imbal-
ances in osteosarcoma from (BALB/cHeNhg × CBA/Ca)
F1 mice as defined by flanking microsatellite markers was
submitted to a semantic web association study using
PosMed [22]. The search parameters were set as: search=
“gene”, condition=“genomic interval”, species=“mouse”,
keyword=“osteosarcoma susceptibility” genome sequence
version=“NCBIm37”. search settings=“all documents”.
With a cut-off p-value of 0.01 (with Bonferroni correc-
tion), the list of gene hits was ranked in the order of
increasing p-value.qRT-PCR measurement of mRNA expression
mRNA (1μg per sample) was extracted from the MC3T3-
E1 preosteoblastic cell line (ATCC code CRL-2593™) and
from primary murine osteoblasts grown in-vitro [43] using
RNAeasy mini kit (Quiagen GmbH, Hilden, Germany)
and reverse transcribed using SuperscriptIII (Life
Technologies, Carlsbad, CA). Quantitative RT-PCR was
done in 96well plates on a StepOne machine using Fast
Sybr Green (both Life Technologies, Carlsbad, CA) and
gene specific primers (Additional file 9). Quantification of
expression levels was done using the ΔΔCt method with a
house keeping gene (TBP) and whole embryo cDNA as
a calibrator.
Rb1 mRNA northern blot
Whole embryo RNA was extracted from day 16 p.c. BALB/
cHeNhg and CBA/Ca embryos by homogenisation in liquid
N2 followed by GTC extraction and phenol/chloroform
purification. For each strain, 6 embryos from 3 different
pregnant mice were used. Following northern blot of 10μg
of each RNA sample, membranes (Roche Diagnostics,
Germany) were probed with a 630 bp 32P labelled mouse
Rb1 cDNA fragment spanning exon 10 to 13. Signals were
quantified using a Storm scanner (Amersham Pharmacia,
Uppsala, Sweden) and Image Quant software (Molecular
Dynamics, Sunnyvale CA, USA). Relative expression levels
(AU) are given as the integrated optical densities of the
Rb1 signal normalized to the sum of the 28S and 18S
RNA signals.
Prediction of promoter function
A 352bp sequence containing the putative Rb1 promoter
from BALB/cHeNhg and CBA/Ca mice, including known
upstream regulatory sequences, the 5’-UTR and the initi-
ation codon ATG was analysed for potential TF binding
sites using MatInspector software (Genomatix Software
GmbH, Munich, Germany) [33,34]. Predefined transcrip-
tion factor weight matrix descriptions are based on the
TRANSFAC-database (all-vertebrates library) with the fol-
lowing default parameter: core similarity = 0.75 and matrix
similarity = calculated optimised.
CAT reporter assay
A fragment of the Rb1 promoter was PCR amplified from
CBA/Ca (451 bp) and BALB/cHeNhg (457 bp) genomic
DNA, using primers 6F and 8.2B, Pwo-polymerase (Peqlab,
Erlangen, Germany) and reaction conditions as given in
Additional file 9. The fragment was cloned into TOPO TA®
vector (Life Technologies, Carlsbad, CA) and directionally
sub-cloned into the pCAT3 basic vector (Promega Corp.
Madison WI, USA) using SacI and XhoI restriction sites.
Plasmids BALB 36, CBA 11 and CBA 14–5 (Additional
file 6) were purified using Quiagen plasmid MaxiPrep kit
(Quiagen GmbH, Hilden, Germany) yielding a final
Rosemann et al. Molecular Cancer 2014, 13:182 Page 9 of 11
http://www.molecular-cancer.com/content/13/1/182concentration of 2 μg/μl and OD260/OD280 absorption
ratios between 1.68 and 1.73. A luciferase expression vec-
tor pGL3® (Promega Corp., Madison WI, USA) under the
control of the RFB LTR served as an internal control for
transfection efficiency. ROS 17/2.8 osteoblasts at a density
of 5*105 cells per 60mm plate were transiently transfected
with 2μg Rb1pCAT and 0.2μg pGL3 using FuGene® lipo-
fection (Roche Diagnostics GmbH, Mannheim, Germany).
After 48h, cells were harvested using reporter lysis buffer
(Promega Corp, Madison WI, USA) and 20μg protein ex-
tracts were assayed for CAT activity using the FastCAT
yellow® assay ((Life Technologies Molecular Probes,
Carlsbad, CA). After thin-layer chromatography, TLC plates
(Sigma Aldrich, Germany) were visualized on a Storm laser
scanner (Amersham Pharmacia, Uppsala, Sweden) and
quantified using Image Quant software (Molecular Dynam-
ics, Sunnyvale CA, USA). Luciferase expression was mea-
sured using the luciferase assay system (Promega Corp.
Madison WI, USA) and an Auto-Lumat LB953 luminometer
(EGG Berthold, Pforzheim, Germany). Promoter activity was
expressed in arbitrary units as AU= 1000* ac-CA/((CA+ ac-
CA)* AUluc), wherein CA and ac-CA are the integral
densities of the chloramphenicol and the acetyl-CA signal,
respectively, and AUluc is the luciferase signal.
Data access
Histological X-ray images of representational cases of
osteosarcoma were deposited to PATHBASE database
(http://eulep.anat.cam.ac.uk, acc.No. PB94713 ff). Rb1 pro-
moter sequence variation was deposited to the European
Nucleotide Archive (http://www.ebi.ac.uk/ena/) and to the
Database of genomic variants archive (http://www.ebi.ac.
uk/dgva/, acc.No. pending).Additional files
Additional file 1: List of annotated genes on mouse chromosome
14, 72 600 000 Mbp - 75 300 000 Mbp, their function, expression in
osteoblasts and evidence for an association with osteosarcoma by
PosMed-search.
Additional file 2: Search for a candidate gene for osteosarcoma
susceptibility using the online mapping and annotation tool
PosMed. The interval on murine chromosome 14 between D14Mit90
(72.6 Mbp) and D14Mit225 (75.3 Mbp) was analyzed for genes for which
literature records have a co-citation with the key-word “Osteosarcoma
Susceptibility”). Co-citation of Rb1 with “Osteosarcoma Susceptibility” in
12 publications occurs with highest significance (p = 5 × 10–53), whereas
four other genes are only indirectly co-cited with the phenotype and
have lower significance (p < 1.2 × 10–20).
Additional file 3: Strain polymorphism in the 3’ UTR used for
genotyping tumor vs. normal tissue. In the lower panel two
representative cases with loss of the BALB- and CBA-alleles are shown, resp.
Additional file 4: mRNA expression of mapped candidate genes at the
OS susceptibility interval in normal osteoblasts and in a MC3T3 pre-
osteoblast cell line. Expression level is relative to TBP housekeeping mRNA.
All values are mean +/−2xSE from 3 independent osteoblast cultures.Additional file 5: Position of transcription factor binding sites
within the Rb1 promoter sequence as predicted using MatInspector
software. The binding sites above the sequence (in black letters) are
present in the BALB / CBA consensus sequence, whereas binding sites
below the sequence (in red letters) are unique for the BALB allele.
Asterisks show TF binding sites as annotated by Zacksenhaus et al.
1993 (Genebank Acc.-No. M86180).
Additional file 6: Reporter constructs for in-vitro analysis of Rb1
promoter activity using CAT reporter constructs fused to 452/458
bp long fragments derived from the BALB/c and CBA-variant of the
Rb1 promoter. As negative control, an inverse orientated CBA-fragment
was used. Base numbering is according to Genebank Acc.-No. M86180.
Additional file 7: Rb1-mRNA expression in BALB/cHeNhg vs. CBA/
Ca mouse embryos 16 days p.c. as measured by northern blot.
Additional file 8: Expression of RB1-protein in established human OS
cell lines (S8a), of Rb1 mRNA in 21 human primary osteosarcoma in
comparison with OS cell lines U2OS (Rb1 positive) and SaOS (Rb1
deficient) (S8b) and Rb1mRNA in murine OS cell lines (S8c). Note that
with a few exceptions, all murine and human osteosarcoma maintain a low
expression of RB1 mRNA and protein expression.
Additional file 9: Primer Sequences and PCR conditions for
genomic and qRT-PCR.
Additional file 10: Protocol for the quantification of allelic imbalance/
loss-of-heterozygosity using genomic PCR of strain - specific
microsatellite markers. Quantitative loss or imbalances of BALB- or CBA
alleles was calibrated for each of the used markers. For this purpose, pure
BALB/c and pure CBA/Ca genomic DNA were mixed in different ratios and
used as template for PCR (27, 30, 33 and 35 cycles). After running the PCR
products on agarose gel electrophoresis and recording the pattern of EtBr
stained BALB- and CBA bands, densitometric measurement of the two
signals was done. The ratio of the experimentally determined BALB- and
CBA alleles was compared with the relative amount of BALB- and CBA-DNA
mixed in the PCR templates and served to draw calibration curves for the
later measurement of allelic ratios in the tumor DNA.
Abbreviations
AU: Arbitrary units; CA: Chloramphenicol; CAT: Chloramphenicol-acetyl-transferase;
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